Repertoire Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, has entered a multi-year strategic collaboration...
Regeneron Pharmaceuticals and Mammoth Biosciences have formed a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and...
The U.S. Food and Drug Administration (FDA) has approved X4 Pharmaceuticals' XOLREMDI (mavorixafor) capsules for use in patients 12 years of age and older...